Viruses 2009, 1(3), 484-509; doi:10.3390/v1030484
Review

HBV and HCV Therapy

* email, ,  and
Received: 13 August 2009; in revised form: 8 October 2009 / Accepted: 19 October 2009 / Published: 22 October 2009
(This article belongs to the Special Issue Hepatitis Viruses)
View Full-Text   |   Download PDF [311 KB, uploaded 22 October 2009]
Abstract: One year of interferon therapy inhibits HBV replication in one third of the patients whereas long-term administration of oral nucleos(t)ide analogues is efficient in most of them, as long as early treatment adaptation in patients with partial virological response and resistance is provided. Following the demonstration of a more potent antiviral effect in terms of sustained virological response (SVR) rates, Pegylated-IFN coupled with Ribavirin has become the standard treatment for chronic hepatitis C, with nearly 65% of all treated patients achieving a SVR. Long-term suppression of HBV and eradication of HCV would halt the progression of chronic hepatitis to cirrhosis, hepatocellular carcinoma and liver decompensation.
Keywords: HBV DNA; nucleos(t)ide analogues; Peg-IFN; resistance; HCV RNA; Ribavirin; SVR
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Lampertico, P.; Aghemo, A.; Viganò, M.; Colombo, M. HBV and HCV Therapy. Viruses 2009, 1, 484-509.

AMA Style

Lampertico P, Aghemo A, Viganò M, Colombo M. HBV and HCV Therapy. Viruses. 2009; 1(3):484-509.

Chicago/Turabian Style

Lampertico, Pietro; Aghemo, Alessio; Viganò, Mauro; Colombo, Massimo. 2009. "HBV and HCV Therapy." Viruses 1, no. 3: 484-509.


Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert